Cardoso Bárbara Vaccari, Custódio Augusto Henrique, Boer Patrícia Aline, Gontijo José Antonio Rocha
Fetal Programming Laboratory and Hydroelectrolyte Metabolism Laboratory, Nucleus of Medicine and Experimental Surgery, Department of Internal Medicine, Faculty of Medical Sciences at State University of Campinas, Campinas 13083-894, São Paulo, Brazil.
Fetal Programming Laboratory and Hydroelectrolyte Metabolism Laboratory, Nucleus of Medicine and Experimental Surgery, Department of Internal Medicine, Faculty of Medical Sciences at State University of Campinas, Campinas 13083-894, São Paulo, Brazil
Biol Open. 2019 Apr 1;8(4):bio038562. doi: 10.1242/bio.038562.
In this study, we hypothesized that blunting of the natriuresis response to intracerebroventricularly (ICV) microinjected adrenergic agonists is involved in the development of hypertension in maternal low-protein intake (LP) offspring. A stainless steel cannula was stereotaxically implanted into the right lateral ventricle (LV), then we evaluated the ICV administration of adrenergic agonists at increasing concentrations, and of α1 and α2-adrenoceptor antagonists on blood pressure and urinary sodium handling in LP offspring relative to an age-matched normal-protein intake (NP) group. We confirmed that epinephrine (Epi) microinjected into the LV of conscious NP rats leads to enhanced natriuresis followed by a reduction in arterial pressure. This response is associated with increased proximal and post-proximal sodium excretion accompanied by an unchanged glomerular filtration rate. The current study showed, in both NP and LP offspring, that the natriuretic effect of Epi injection into the LV was abolished by prior local microinjection of an α1-adrenoceptor antagonist (prazosin). Conversely, LV α2-adrenoceptor antagonist (yohimbine) administration potentiated the action of Epi. The LV yohimbine pretreatment normalized urinary sodium excretion and reduced the blood pressure in LP compared with age-matched NP offspring. These are, as far as we are aware, the first results showing the role of central adrenergic receptors' interaction on hypertension pathogenesis in maternal LP fetal-programming offspring. This study also provides good evidence for the existence of central nervous system adrenergic mechanisms consisting of α1 and α2-adrenoceptors, which work reciprocally on the control of renal sodium excretion and blood pressure. Although the precise mechanism of the different natriuretic response of NP and LP rats is still uncertain, these results lead us to speculate that inappropriate neural adrenergic pathways might have significant effects on tubule sodium transport, resulting in the inability of the kidneys to control hydrosaline balance and, consequently, an increase in blood pressure.
在本研究中,我们假设对脑室内(ICV)微量注射肾上腺素能激动剂的利钠反应减弱与母体低蛋白摄入(LP)子代高血压的发生有关。将不锈钢套管立体定向植入右侧脑室(LV),然后我们评估了在年龄匹配的正常蛋白摄入(NP)组的LP子代中,递增浓度的肾上腺素能激动剂以及α1和α2肾上腺素能拮抗剂经ICV给药对血压和尿钠处理的影响。我们证实,向清醒的NP大鼠LV内微量注射肾上腺素(Epi)会导致利钠作用增强,随后动脉压降低。这种反应与近端和近端后钠排泄增加相关,而肾小球滤过率不变。当前研究表明,在NP和LP子代中,预先局部微量注射α1肾上腺素能拮抗剂(哌唑嗪)可消除向LV内注射Epi的利钠作用。相反,给予LVα2肾上腺素能拮抗剂(育亨宾)可增强Epi的作用。与年龄匹配的NP子代相比,LV育亨宾预处理可使LP子代的尿钠排泄正常化并降低血压。据我们所知,这些是首次显示中枢肾上腺素能受体相互作用在母体LP胎儿编程子代高血压发病机制中作用的结果。本研究还为存在由α1和α2肾上腺素能受体组成的中枢神经系统肾上腺素能机制提供了有力证据,这些机制在肾钠排泄和血压控制方面相互作用。尽管NP和LP大鼠不同利钠反应的确切机制仍不确定,但这些结果使我们推测,不适当的神经肾上腺素能途径可能对肾小管钠转运有显著影响,导致肾脏无法控制水盐平衡,从而使血压升高。